Apixaban

Drug Profile

Apixaban

Alternative Names: BMS-562247; BMS-562247-01; Eliquis

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Pfizer
  • Class 2 ring heterocyclic compounds; Amides; Anticoagulants; Antithrombotics; Lactams; Phenyl ethers; Pyrazoles; Pyridones; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
  • Phase III Acute coronary syndromes

Most Recent Events

  • 23 Feb 2017 Bristol-Myers Squibb has patent protection for apixaban in Japan (Pfizer Form 10-K, February 2017)
  • 01 Jan 2017 Phase-II clinical trials in Thromboembolism (In adolescents, In children, In infants, Prevention) in USA (PO, Tablet) (NCT02981472)
  • 01 Jan 2017 Phase-II clinical trials in Thromboembolism (In adolescents, In infants, In children, Prevention) in USA (PO, Liquid) (NCT02981472)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top